EUVIMEDEUVIMED entdecken
Crossref

CYP3A5 Polymorphism in Renal Transplantation: A Key to Personalized Immunosuppression

Amit S Pasari, Manish R Balwani, Prasad Gurjar, Charulata Bawankule, Amol Bhawane, Priyanka Tolani, Pranjal Kashiv, Shubham Dubey, Vijay M Katekhaye

Transplantation Proceedings · 2023-06 · 55 (5) · 1305-1309

DOI: 10.1016/j.transproceed.2023.02.043 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplantation Proceedings, 2023-06. Verfasst von Amit S Pasari und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Saraswati Kidney Care Center, Nagpur, Maharashtra, India; Department of Nephrology, Jawaharlal Nehru Medical College, Sawan…. Hauptthemen laut MEDLINE: Tacrolimus, Kidney Transplantation. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Tacrolimus is essential for the maintenance of immunosuppression after a kidney transplant. CYP3A5 is the gene that metabolizes tacrolimus, and polymorphism in this gene affects the metabolizing status. AIM: To assess the genetic polymorphism status of patients undergoing kidney transplantation and determine its impact on graft function and complications in the post-transplant period. METHODS: We retrospectively included the patients who had undergone a kidney transplant and had positive genetic polymorphism of the CYP3A5 gene. Based on loss of alleles, patients were categorized as non-expresser (loss of both alleles), intermediate expresser (loss of one allele), and expresser (no loss of allele) denoted by CYP3A5*3/*3, CYP3A5*1/*3, and CYP3A5*1/*1, respectively. Data were analyzed with descriptive statistics. RESULTS: Of 25 patients, 60%, 32%, and 8% were non-expressers, intermediate-expressers, and expressers, respectively. The mean tacrolimus trough concentration to dose ratio after 6 months of the transplant was higher in non-expressers than intermediate-expressers and expressers (213 vs 85 and 46 ng/mL/mg/kg/d, respectively). The graft function was normal in all 3 groups except for graft rejection 1 patient in the expresser group. Compared with expressers, urinary tract infections (42.9% and 62.5%) and new-onset diabetes after transplantation (28.6% and 12.5%) were more frequent in non-expresser and intermediate expressers, respectively. The proportion of patients developing new-onset diabetes after transplantation was lower with the pre-transplant diagnosis of CYP3A5 polymorphism (16.7% vs 23.1%). CONCLUSION: Genotype-based dosing of tacrolimus helps achieve the desired therapeutic concentrations that can help to optimize graft outcomes and reduce the tacrolimus-related adverse effects. Pre-transplant evaluation of CYP3A5 can be more helpful in planning treatment strategies for optimized outcomes after kidney transplantation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TacrolimusKidney TransplantationHumansImmunosuppressive AgentsCytochrome P-450 CYP3ARetrospective StudiesPolymorphism, GeneticImmunosuppression TherapyGenotypeGraft RejectionPolymorphism, Single Nucleotide

Substanzen

TacrolimusImmunosuppressive AgentsCytochrome P-450 CYP3ACYP3A5 protein, human

Autor:innen und Institutionen

  • Department of Nephrology, Saraswati Kidney Care Center, Nagpur, Maharashtra, India; Department of Nephrology, Jawaharlal Nehru Medical College, Sawangi, Wardha, Maharashtra, India.
  • Department of Nephrology, Saraswati Kidney Care Center, Nagpur, Maharashtra, India; Department of Nephrology, Jawaharlal Nehru Medical College, Sawangi, Wardha, Maharashtra, India. Electronic address: balwani.manish@yah…
  • Department of Nephrology, Jawaharlal Nehru Medical College, Sawangi, Wardha, Maharashtra, India.
  • Department of Nephrology, Saraswati Kidney Care Center, Nagpur, Maharashtra, India.
  • Department of Nephrology, AIIMS, Nagpur, Maharashtra, India.
  • Department of Internal Medicine, Jawaharlal Nehru Medical College, Sawangi, Wardha, Maharashtra, India.

Zitieren

APA

Pasari, A. S., Balwani, M. R., Gurjar, P., Bawankule, C., Bhawane, A., Tolani, P., Kashiv, P., Dubey, S., & Katekhaye, V. M. (2023). CYP3A5 Polymorphism in Renal Transplantation: A Key to Personalized Immunosuppression. Transplantation Proceedings, 55(5), 1305-1309. https://doi.org/10.1016/j.transproceed.2023.02.043

Vancouver

Pasari AS, Balwani MR, Gurjar P, Bawankule C, Bhawane A, Tolani P, et al. CYP3A5 Polymorphism in Renal Transplantation: A Key to Personalized Immunosuppression. Transplantation Proceedings. 2023;55(5):1305-1309. doi:10.1016/j.transproceed.2023.02.043

BibTeX
@article{Pasari2023,
  author = {Pasari, Amit S and Balwani, Manish R and Gurjar, Prasad and Bawankule, Charulata and Bhawane, Amol and Tolani, Priyanka and Kashiv, Pranjal and Dubey, Shubham and Katekhaye, Vijay M},
  title = {CYP3A5 Polymorphism in Renal Transplantation: A Key to Personalized Immunosuppression},
  journal = {Transplantation Proceedings},
  year = {2023},
  volume = {55},
  number = {5},
  pages = {1305--1309},
  doi = {10.1016/j.transproceed.2023.02.043}
}
Kostenlos starten →